+34 914 524 941    info@algenex.com

Corporate Strategy

ALGENEX protects its proprietary scientific/technology developments by patents and commercially exploit them by co-developments or licenses to pharmaceutical or biotechnology companies, including specific tailored contract services of recombinant protein production as CMO.

 

Our corporate strategy consist on:
Potential business niches
  • Recombinant protein production technologies
  • Human and animal vaccines
  • Diagnostic reagents
  • Supply agreements for commercial and R&D quantities
Business model
ALGENEX commercially exploit its patents and know-how by co-developments or licenses to pharmaceutical or biotechnology companies, including specific tailored contract services of recombinant protein production.
Vision
ALGENEX pretends the acquisition of an international leadership position as:
  • Global leader company in the development of industrial production technology platforms based on baculovirus expression vectors in insect cells and insects used as small living biofactories.
  • Company able to develop cost-effective and highly immunogenic subunit vaccines;
  • Company with a insect-based factory for the production of ALGENEX proprietary vaccines and for the production of recombinant molecules for third companies. First vaccines will reach the market in around 4 years.
ALGENEX protects its proprietary scientific/technology developments by patents and commercially exploit them by co-developments or licenses to pharmaceutical or biotechnology companies, including specific tailored contract services of recombinant protein production as CMO.

 

Our corporate strategy consist on:
Potential business niches
  • Recombinant protein production technologies
  • Human and animal vaccines
  • Diagnostic reagents
  • Supply agreements for commercial and R&D quantities
Business model
ALGENEX commercially exploit its patents and know-how by co-developments or licenses to pharmaceutical or biotechnology companies, including specific tailored contract services of recombinant protein production.
Vision
ALGENEX pretends the acquisition of an international leadership position as:
  • Global leader company in the development of industrial production technology platforms based on baculovirus expression vectors in insect cells and insects used as small living biofactories.
  • Company able to develop cost-effective and highly immunogenic subunit vaccines;
  • Company with a insect-based factory for the production of ALGENEX proprietary vaccines and for the production of recombinant molecules for third companies. First vaccines will reach the market in around 4 years.